Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDO2 | P48775 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 3/20 | 0.32 |
| ▸ | RAB9A | P51151 | 3/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | PPARA | Q07869 | 1/20 | 0.30 |
| ▸ | TP53 | P04637 | 1/20 | 0.30 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20553989 | 0.98 | ALDH1A1 (0.37) | TDO2ALDH1A1LMNAPOLBCYP2C19 | |
| SCHEMBL20554254 | 0.98 | ALDH1A1 (0.37) | TDO2ALDH1A1LMNAPOLBCYP2C19 | |
| SCHEMBL3726887 | 0.98 | ALDH1A1 (0.37) | TDO2ALDH1A1LMNAPOLBCYP2C19 | |
| SCHEMBL20554022 | 0.95 | — | — | |
| SCHEMBL1431256 | 0.91 | — | — | |
| SCHEMBL20561676 | 0.77 | — | — | |
| SCHEMBL24623064 | 0.60 | CYP2C19 (0.55) | ALDH1A1LMNAPOLBCYP2C19NPC1 | |
| SCHEMBL9879297 | 0.60 | ALDH1A1 (0.39) | ALDH1A1LMNAPOLBCYP2C19CYP1A2 | |
| SCHEMBL14305108 | 0.59 | CYP2C19 (0.53) | ALDH1A1LMNAPOLBCYP2C19NPC1 | |
| SCHEMBL8628112 | 0.58 | ALDH1A1 (0.37) | ALDH1A1LMNAPOLBCYP2C19CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9487494-B2 | Cyclic hydrocarbon compounds for the treatment of diseases | LEO PHARMA A/S (DK) | 2016-11-08 | — | — | US | claimed |
| US-20100317582-A1 | NOVEL CYCLIC HYDROCARBON COMPOUNDS FOR THE TREATMENT OF DISEASES | LEO PHARMA A/S (DK) | 2010-12-16 | — | — | US | claimed |
| EP-2234961-A2 | NOVEL CYCLIC HYDROCARBON COMPOUNDS FOR THE TREATMENT OF DISEASES | LEO PHARMA A/S (DK) | 2010-10-06 | — | — | EP | claimed |
| WO-2009065406-A2 | NOVEL CYCLIC HYDROCARBON COMPOUNDS FOR THE TREATMENT OF DISEASES | LEO PHARMA A/S (DK) | 2009-05-28 | — | — | WO | claimed |
| EP-4023640-A1 | PHENYLIMIDAZOLE COMPOUND | Otsuka Pharmaceutical Factory, Inc. (JP) | 2022-07-06 | — | — | EP | disclosed |
| CN-113200962-A | Phenylimidazole compounds | 株式会社大塚制药工场 | 2021-08-03 | — | — | CN | disclosed |
| CN-108430977-B | Phenylimidazole compounds | 株式会社大塚制药工场 | 2021-06-08 | — | — | CN | disclosed |
| US-10570117-B2 | Phenylimidazole compound | OTSUKA PHARMACEUTICAL FACTORY, INC. (JP) | 2020-02-25 | — | — | US | disclosed |
| US-20180354930-A1 | PHENYLIMIDAZOLE COMPOUND | OTSUKA PHARMACEUTICAL FACTORY, INC. (JP) | 2018-12-13 | — | — | US | disclosed |
| EP-3401310-A1 | PHENYLIMIDAZOLE COMPOUND | Otsuka Pharmaceutical Factory, Inc. (JP) | 2018-11-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10570117-B2 | Phenylimidazole compound | LPL, PNLIP, LIPC | TDO2 3504/4885ALDH1A1 263/4885LMNA 1063/4885 |
| US-20100317582-A1 | NOVEL CYCLIC HYDROCARBON COMPOUNDS FOR THE TREATMENT OF DISEASES | ARNT, AHR, CYP27A1 | TDO2 973/4885ALDH1A1 1743/4885LMNA 1156/4885 |
| US-20180354930-A1 | PHENYLIMIDAZOLE COMPOUND | PNLIP, PLIN1, HDAC11 | TDO2 4641/4885ALDH1A1 457/4885LMNA 3128/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.